The program focuses on antibiotic resistance in urinary tract infections, with applications open until Nov 20.
Seegene Inc has partnered with Springer Nature to open applications for the 2025-2026 Nature Awards MDx Impact Grants, offering up to $600,000 in research funding to advance molecular diagnostics for antibiotic-resistant urinary tract infections.
The third cycle of the program focuses specifically on antibiotic resistance in urinary tract infections, inviting researchers worldwide to submit product development ideas and clinical research projects. Applications are open until Nov 20, with final awardees to be announced in August 2026.
Selected researchers will receive funding along with access to Seegene’s syndromic PCR assays, consumables, instruments, and software to support diagnostic development. Applicants can propose up to 18 resistance genes associated with urinary tract infections as assay targets based on unmet clinical needs.
“Seegene’s role is to provide the tools and technologies to scientists and researchers that can turn innovative ideas into real solutions,” says Dr Jik Young Park, vice president and head of Seegene’s R&D division, in a release. “In close collaboration with Springer Nature, we are fostering global research efforts by supporting scientists with both funding and access to our syndromic PCR technologies.”
Supporting Global Diagnostic Innovation
The program aims to advance Seegene’s Technology-Sharing Initiative and expand access to molecular diagnostics worldwide. The grants are designed to complement ongoing global initiatives in diagnostics by providing researchers with resources to accelerate practical solutions for antibiotic resistance challenges.
“As one of the global leading scientific publishers, Springer Nature is committed to building platforms that connect scientists and amplify innovative research,” says Richard Hughes, vice president publishing, Nature and Content Services, Springer Nature, in a release. “Through this program, we aim to help researchers develop diagnostic solutions that can make a difference in healthcare worldwide.”
The 2024-2025 cycle supported projects focused on rapid detection of ViruResist Klebsiella pneumoniae and multiplex PCR assay development for viral detection in immunocompromised patients, demonstrating the program’s impact across multiple areas of clinical need.
The Nature Awards MDx Impact Grants represent part of Seegene’s broader vision to create “a world free from all diseases” by supporting the development of molecular diagnostics that address pressing public health challenges, particularly antibiotic resistance in healthcare settings.
ID 69191607 © One Photo | Dreamstime.com
